TrialPloS one2020

Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy.

Zongwei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.